A Comprehensive Monograph on Neostigmine (DB01400)

I. Introduction and Executive Summary

Preamble

Neostigmine is a parasympathomimetic agent that has served as a cornerstone of clinical practice in anesthesiology and neurology for nearly a century. As a synthetic small molecule, its primary pharmacological action is the reversible inhibition of the enzyme acetylcholinesterase (AChE).[1] This mechanism allows for the potentiation of acetylcholine at cholinergic synapses, a principle that has been harnessed for a range of therapeutic applications. The drug’s enduring presence in medicine is a testament to its reliable, predictable, and well-understood profile.

Historical Context

Patented in 1931 and receiving its initial U.S. Food and Drug Administration (FDA) approval in 1939, Neostigmine has a long and storied history of clinical use.[4] Its name is derived from the Greek

neos, meaning "new," and its design was inspired by the naturally occurring alkaloid physostigmine, representing an early triumph of rational drug design aimed at improving upon a natural prototype.[4]

Core Clinical Utility

The principal FDA-approved indication for Neostigmine is the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) following surgery.[1] In this setting, it accelerates the recovery of muscle function, allowing for the safe return of spontaneous ventilation and airway reflexes. Beyond this primary role, Neostigmine has significant clinical applications, including the symptomatic treatment of myasthenia gravis, the management of acute colonic pseudo-obstruction (Ogilvie syndrome), and the treatment of postoperative and neurogenic urinary retention.[4]

Pharmacological Hallmark

A defining feature of Neostigmine is its chemical structure as a quaternary ammonium compound. This imparts a permanent positive charge, rendering the molecule highly polar and ionized at physiological pH. Consequently, Neostigmine does not readily cross the blood-brain barrier.[2] This pharmacological hallmark confines its actions primarily to the peripheral nervous system, distinguishing it fundamentally from tertiary amine cholinesterase inhibitors like physostigmine and shaping its entire clinical profile.[1]

Executive Summary of Key Findings

This report provides a comprehensive analysis of Neostigmine, synthesizing data on its chemistry, pharmacology, clinical efficacy, and regulatory standing. Key findings indicate that Neostigmine possesses a predictable but manageable safety profile, dominated by cholinergic side effects that are a direct extension of its mechanism of action. The clinical use of Neostigmine, particularly for neuromuscular blockade reversal, is predicated on the mandatory co-administration of anticholinergic agents (e.g., atropine, glycopyrrolate) to mitigate these unwanted muscarinic effects. While it remains an essential and cost-effective generic medication, its role is evolving in the modern therapeutic landscape, especially with the advent of newer, more targeted agents like Sugammadex for neuromuscular blockade reversal. Despite this, Neostigmine's broad utility and long history of use ensure its continued, stable position in the global pharmacopeia.[1]

II. Chemical Identity and Physicochemical Properties

Nomenclature and Identifiers

Neostigmine is identified by a standardized set of chemical and regulatory codes that ensure its precise identification across scientific literature, clinical practice, and regulatory databases.

• Drug Name: Neostigmine [1]
• DrugBank ID: DB01400 [4]
• CAS Number: 59-99-4 (for the active cation) [4]
• IUPAC Name: 3-{oxy}-N,N,N-trimethylbenzenaminium [4]
• Synonyms and Brand Names: The drug is known by numerous synonyms and trade names globally, reflecting its long history and widespread use. Common names include Prostigmin, Bloxiverz, Vagostigmin, Polstigmine, Eustigmin, Synstigmin, and Proserine.[2] A comprehensive list of international brand names includes Normastigmin (Austria), Intrastigmina (Italy), Stigmosan (Hungary), and Tilstigmin (India), among many others.[20]

Chemical Structure and Class

The chemical structure of Neostigmine is central to its pharmacological activity.

• Chemical Formula: C12​H19​N2​O2+​ [10]
• Molecular Weight: 223.29 g/mol (for the cation) [2]
• Structural Description: Neostigmine is a synthetic quaternary ammonium ion. Its structure features an anilinium core with three methyl groups attached to the primary nitrogen, conferring the permanent positive charge. A 3-[(dimethylcarbamoyl)oxy] substituent is attached to the benzene ring. It is classified as a carbamate ester and is considered a simplified synthetic analog of the natural alkaloid physostigmine.[2]
• Chemical Taxonomy: According to the Classyfire system, Neostigmine belongs to the Kingdom of Organic compounds, the Super Class of Benzenoids, and the Class of Phenoxy compounds.[14]

Associated Salts

In pharmaceutical preparations, the positively charged Neostigmine cation is paired with a counter-ion to form a salt. The specific salt affects the overall molecular weight and formulation properties but does not alter the pharmacological activity of the Neostigmine cation itself. The most common salts are:

• Neostigmine Methylsulfate: CAS Number 51-60-5; used in injectable formulations.[4]
• Neostigmine Bromide: CAS Number 114-80-7; historically used in oral tablet formulations.[2]

Physicochemical Properties

• Solubility and Appearance: Neostigmine is described as a water-soluble, ionized compound, which typically appears as a white crystalline powder.[1] While the base compound has a predicted low water solubility (0.0677 mg/mL), its salt forms used in medicine are readily soluble, facilitating the preparation of aqueous solutions for injection.[14] The methylsulfate salt has been noted to be soluble in DMSO.[21] This distinction between the properties of the base cation and its formulated salts is important for understanding its behavior in different contexts.
• Storage and Stability: Neostigmine preparations are typically stored in a refrigerator at 2-8°C or at controlled room temperature (20-25°C), and must be protected from light to ensure stability.[10]
• Spectral Data: The molecule exhibits notable UV/VIS absorption peaks at 261 nm, 267 nm, and 225 nm. Its proton nuclear magnetic resonance (1H NMR) spectrum shows characteristic shifts corresponding to its aromatic and alkyl hydrogens.[4]

The quaternary ammonium structure is the single most important determinant of Neostigmine's entire pharmacokinetic and pharmacodynamic profile. The permanent positive charge on the nitrogen atom renders the molecule highly polar and fully ionized at physiological pH.[1] This polarity is the direct reason for its high water solubility and, critically, its inability to passively diffuse across lipid-rich biological membranes. The most significant of these is the blood-brain barrier (BBB). This barrier exclusion prevents Neostigmine from entering the central nervous system (CNS), thereby confining its pharmacological effects to the periphery.[1] This peripheral restriction is what makes Neostigmine a safer and more targeted agent for applications like neuromuscular blockade reversal compared to CNS-penetrating AChE inhibitors such as the tertiary amine physostigmine. Furthermore, this same polarity is responsible for its very poor oral bioavailability, estimated at only 1-2%, which necessitates parenteral administration (intravenous, intramuscular, or subcutaneous) to achieve reliable and predictable clinical effects.[1] Thus, this single structural feature dictates its primary routes of administration, its principal clinical uses, and its relative safety profile.

III. Comprehensive Pharmacological Profile

A. Pharmacodynamics: Mechanism of Action

The pharmacodynamic effects of Neostigmine are rooted in its ability to modulate the cholinergic nervous system through a well-defined mechanism.

• Primary Mechanism: Neostigmine is a reversible, competitive inhibitor of the enzyme acetylcholinesterase (AChE).[1] AChE is responsible for the rapid hydrolysis of the neurotransmitter acetylcholine (ACh) into its inactive components, choline and acetic acid, at cholinergic synapses. By inhibiting AChE, Neostigmine effectively decreases the rate of ACh degradation, leading to an increased concentration and prolonged half-life of ACh in the synaptic cleft.[1]
• Molecular Interaction with AChE: The interaction with AChE is specific and involves two key sites on the enzyme. The positively charged quaternary nitrogen of Neostigmine binds via electrostatic forces to the enzyme's peripheral anionic site. Simultaneously, the carbamate ester group of Neostigmine forms a transient covalent bond with a serine residue within the enzyme's catalytic (esteratic) site. This process, known as serine carbamylation, creates a carbamoylated enzyme complex that is far more stable and hydrolyzes much more slowly than the naturally formed acetylated enzyme complex.[1] This slow hydrolysis results in the temporary, reversible inactivation of AChE.
• Receptor Effects: The accumulation of ACh at the synapse leads to enhanced stimulation of both major types of cholinergic receptors:
• Nicotinic Receptors: Located at the neuromuscular junction (NMJ) of skeletal muscle and in autonomic ganglia. Stimulation at the NMJ is the basis for its therapeutic effect in reversing neuromuscular blockade and treating myasthenia gravis.[3]
• Muscarinic Receptors: Located on effector organs of the parasympathetic nervous system, including cardiac muscle, smooth muscle (e.g., in the GI tract, bronchi, bladder), and exocrine glands (e.g., salivary, sweat).[3] Stimulation of these receptors is responsible for the majority of Neostigmine's side effects.
• Additional Mechanisms: Beyond AChE inhibition, Neostigmine may exert other effects that contribute to its overall action. It has been shown to inhibit certain voltage-gated potassium channels in motor neurons, which can prolong the action potential duration and thereby increase the presynaptic release of ACh.[8] Additionally, some evidence suggests Neostigmine may have a direct cholinomimetic effect, weakly activating nicotinic receptors at the NMJ itself.[25]
• Ceiling Effect: A critical concept in Neostigmine's pharmacology is the "ceiling effect." Because its action is dependent on amplifying the effect of endogenously released ACh, its ability to enhance muscle strength is ultimately limited by the amount of ACh available at the presynaptic terminal. Once the available ACh has produced its maximal effect, further increases in Neostigmine dose will not produce a greater therapeutic response and may instead lead to paradoxical weakness due to receptor desensitization.[8]

B. Pharmacokinetics: ADME Profile

The absorption, distribution, metabolism, and excretion (ADME) profile of Neostigmine is dictated by its physicochemical properties, particularly its status as a charged, polar molecule.

• Absorption: When administered intravenously (IV), Neostigmine has 100% bioavailability, ensuring immediate and complete entry into the systemic circulation. It is also reliably absorbed following intramuscular (IM) or subcutaneous (SC) injection. In contrast, oral absorption is extremely poor and erratic, with a bioavailability of only 1-2%, making the oral route unsuitable for acute or predictable clinical effects.[1]
• Distribution:
• Protein Binding: Neostigmine exhibits low to moderate binding to plasma proteins, with 15% to 25% bound to human serum albumin.[1] This leaves a large fraction of the drug free to interact with target tissues.
• Volume of Distribution (Vd​): The volume of distribution is reported to be in the range of 0.12 to 1.4 L/kg, indicating that the drug distributes primarily within the extracellular fluid and does not extensively accumulate in tissues.[1]
• CNS Penetration: As a charged quaternary ammonium compound, Neostigmine is ionized at physiological pH and cannot effectively cross the lipid-rich blood-brain barrier. This property confines its pharmacological activity to the periphery.[1]
• Metabolism: Neostigmine is eliminated from the body through two main pathways. It undergoes hydrolysis by plasma and tissue cholinesterases, and it is also metabolized by microsomal enzymes in the liver.[1]
• Elimination:
• Route: The drug and its metabolites are primarily excreted by the kidneys. Studies indicate that up to 70% of an administered dose is excreted in the urine as unchanged drug, with the remainder appearing as metabolites.[1]
• Elimination Half-Life: The elimination half-life (t1/2​) of Neostigmine is relatively short but can vary significantly depending on patient age and renal function. The commonly cited range is 50 to 90 minutes.[4] Other reports place the range between 24 and 113 minutes.[1] One early study in surgical patients reported a faster elimination half-life of 15 to 32 minutes, highlighting the potential for inter-patient variability.[28]

The pharmacology of Neostigmine presents a classic "double-edged sword." Its core therapeutic value—increasing ACh levels to restore function at nicotinic receptors at the neuromuscular junction—is inextricably linked to its primary liability: the simultaneous increase of ACh at muscarinic receptors throughout the body.[3] This global increase in ACh inevitably leads to a cascade of predictable, dose-dependent adverse effects, including bradycardia, bronchoconstriction, hypersalivation, and gastrointestinal hypermotility.[1] These are not idiosyncratic reactions but are the direct, expected pharmacological consequences of its non-selective mechanism. This reality mandates a specific clinical strategy: the co-administration of a selective muscarinic antagonist, such as atropine or glycopyrrolate. This combination therapy effectively blocks the unwanted muscarinic effects while allowing the desired nicotinic effects at the NMJ to proceed, thereby creating a functionally targeted therapy from a non-selective agent.[1]

A second critical consideration arising from its pharmacology is the potential for a pharmacokinetic mismatch, which introduces a significant clinical risk. Neostigmine has a finite duration of action, with a half-life of approximately 50-90 minutes and a duration of effect lasting about 55-75 minutes.[1] In contrast, nondepolarizing NMBAs have a wide range of durations. Longer-acting agents like pancuronium can have effects that persist long after a single dose of Neostigmine has been metabolized and eliminated.[24] Should this occur, the patient is at risk for "recurarization"—a return of muscle weakness or paralysis after an initial period of recovery. This poses a major safety concern, particularly for respiratory function after tracheal extubation. This risk is further amplified in patients with renal impairment, as both Neostigmine and many NMBAs are cleared by the kidneys. Renal dysfunction can prolong the half-life of both drugs, but potentially to different and unpredictable degrees, exacerbating the mismatch.[1] This potential for pharmacokinetic mismatch is the primary rationale behind the strict clinical guidelines that emphasize the use of quantitative neuromuscular monitoring (e.g., achieving a TOF ratio greater than 0.9) to confirm

sustained and adequate recovery, rather than relying solely on initial signs of reversal, before a patient is extubated.[1]

IV. Clinical Applications and Therapeutic Efficacy

A. Reversal of Non-Depolarizing Neuromuscular Blockade (Primary FDA-Approved Indication)

The foremost clinical application of Neostigmine is in the field of anesthesiology for the reversal of neuromuscular blockade.

• Clinical Rationale: During many surgical procedures, nondepolarizing NMBAs (e.g., rocuronium, vecuronium, cisatracurium, pancuronium) are administered to induce muscle paralysis, facilitating tracheal intubation and optimizing surgical conditions. At the conclusion of surgery, it is imperative to restore normal neuromuscular function to ensure the patient can breathe spontaneously and protect their airway. Neostigmine antagonizes the competitive block of these agents at the NMJ, thereby expediting the return of muscle tone and function.[1]
• Efficacy: The administration of Neostigmine effectively reduces the time to recovery of neuromuscular function. The standard objective measure of adequate recovery is a train-of-four (TOF) ratio of ≥0.9. Neostigmine typically achieves this endpoint within 10 to 20 minutes of IV administration, with its peak antagonistic effect occurring between 7 and 10 minutes.[1]
• Clinical Benefit: The ability to reliably reverse neuromuscular blockade provides several clinical advantages. It allows anesthesiologists to maintain an adequate level of paralysis through the final stages of a surgical procedure, such as wound closure, reducing the risk of patient movement. It also permits the earlier discontinuation of volatile or intravenous anesthetic agents and facilitates a more rapid transition away from mechanical ventilation.[5]

B. Management of Myasthenia Gravis (Historical and Off-Label Use)

Neostigmine has a long-standing role in the diagnosis and management of myasthenia gravis, an autoimmune disorder characterized by antibody-mediated destruction of nicotinic ACh receptors at the NMJ.

• Rationale: In myasthenia gravis, the number of functional ACh receptors is severely reduced. By inhibiting AChE, Neostigmine increases the concentration of ACh in the synaptic cleft, enhancing the probability that ACh will bind to the remaining receptors and trigger muscle contraction. This leads to a symptomatic improvement in muscle tone and strength.[2]
• Use in Diagnosis: The "Neostigmine test" is a classic diagnostic tool for myasthenia gravis. It involves the parenteral administration of Neostigmine (e.g., 0.022-0.04 mg/kg IM) along with an anticholinergic like atropine. A marked and objective improvement in muscle strength following the injection is considered a positive test, supporting the diagnosis.[1]
• Symptomatic Treatment: Neostigmine has been used for the daily management of myasthenic symptoms, administered via IM, SC, or, historically, oral routes.[1] However, for long-term oral therapy, pyridostigmine is now generally the preferred agent due to its longer duration of action, which allows for less frequent dosing and smoother control of symptoms, and a potentially more favorable side-effect profile.[22]

C. Other Off-Label and Historical Indications

Neostigmine's ability to stimulate cholinergic receptors on smooth muscle has led to its use in several other clinical contexts, primarily off-label.

• Acute Colonic Pseudo-obstruction (Ogilvie Syndrome): In this condition, patients experience massive dilation of the colon in the absence of a mechanical blockage. Neostigmine is often used as a second-line therapy when initial conservative measures, such as bowel rest and decompression, have failed. It is considered an effective treatment but requires careful cardiac monitoring during administration.[1]
• Postoperative and Neurogenic Urinary Retention: Neostigmine can be used to increase detrusor muscle tone in the bladder, promoting urination in cases of non-obstructive urinary retention, such as that occurring after surgery or in patients with neurogenic bladder dysfunction.[4]
• Postoperative Intestinal Atony (Paralytic Ileus): It has been used both prophylactically after surgery and for the treatment of established paralytic ileus to stimulate gastrointestinal motility and restore peristalsis.[27]
• Adjunctive Analgesia: There is some evidence for the use of intrathecal or epidural Neostigmine as an adjunct to other analgesics. By increasing ACh levels in the spinal cord, it can modulate nociceptive signaling pathways. However, its use in this context is limited by a high incidence of dose-related side effects, particularly nausea and vomiting.[26]

D. Review of Clinical Trial Data

The efficacy and safety of Neostigmine have been evaluated in numerous clinical trials, particularly in comparison to newer agents.

• Comparator Trials vs. Sugammadex: A large body of clinical trial evidence compares Neostigmine with Sugammadex for the reversal of NMB.[12] These studies, including several registered on clinicaltrials.gov (e.g., NCT03656614, NCT03137290, NCT06136585), consistently demonstrate that Sugammadex provides a significantly faster and more predictable reversal of rocuronium- or vecuronium-induced blockade, especially from deep levels of paralysis. Furthermore, meta-analyses have shown that Sugammadex is associated with a lower risk of postoperative residual curarization and fewer adverse effects like nausea, vomiting, and cardiovascular complications compared to Neostigmine.[1]
• Investigational Trials: Neostigmine continues to be explored for other potential uses. For example, trial NCT02370433 investigated its use in combination with glycopyrronium as a prokinetic agent to manage neurogenic bowel dysfunction in patients with spinal cord injuries.[36]
• Myasthenia Gravis Trials: As noted in a comprehensive Cochrane review, there is a conspicuous lack of large, modern, randomized controlled trials evaluating the efficacy of AChE inhibitors like Neostigmine in myasthenia gravis. This is not due to a lack of efficacy, but rather because the symptomatic benefit observed in decades of clinical practice and observational studies is considered so profound and immediate that conducting a placebo-controlled trial, which would deprive patients of effective treatment, would be difficult to justify on ethical grounds.[37]

V. Dosing, Formulations, and Administration Protocols

A. Available Formulations and Brand Names

Neostigmine is marketed globally in several formulations, primarily for parenteral use.

• Injectable Solution (Neostigmine Methylsulfate): This is the most common form and is available in single-dose vials, multiple-dose vials, and convenient single-dose pre-filled syringes.[7]
• Strengths: Standard concentrations include 0.5 mg/mL, 1 mg/mL, and 2.5 mg/mL.[24]
• Brand Names: Common brand names for the injectable formulation include Bloxiverz and the historical brand Prostigmin.[4] It is also widely available as a generic product.
• Oral Tablets (Neostigmine Bromide): Historically, 15 mg tablets were available under the brand name Prostigmin for the chronic management of myasthenia gravis. However, this oral formulation is no longer commercially available in the United States.[29]
• Combination Product: To simplify administration and reduce the risk of medication errors, a fixed-dose combination product, PREVDUO, is available. It is a pre-filled syringe containing Neostigmine methylsulfate (1 mg/mL) co-formulated with the anticholinergic agent Glycopyrrolate (0.2 mg/mL), specifically for the reversal of NMB.[13]

B. Dosing Regimens by Indication

Dosing of Neostigmine must be carefully individualized based on the clinical indication, patient weight, and the specific clinical context.

• Reversal of NMB (Adults & Pediatrics):
• Dose: The standard IV dose is 0.03 to 0.07 mg/kg, administered slowly over at least 1 minute.[1]
• Maximum Dose: The total cumulative dose should not exceed 0.07 mg/kg or 5 mg, whichever is less.[7]
• Dose Selection: The choice of dose within the recommended range is guided by the depth of the existing neuromuscular blockade and the pharmacokinetic profile of the NMB agent being reversed.
• A lower dose (e.g., 0.03 mg/kg) is appropriate for reversing shallower blocks (e.g., when a second twitch in the TOF is present) or for reversing shorter-acting NMBAs like rocuronium.[7]
• A higher dose (e.g., 0.07 mg/kg) is recommended for reversing deeper blocks or longer-acting NMBAs like vecuronium or pancuronium, or when more rapid recovery is desired.[7]
• Myasthenia Gravis (Adults):
• Injectable: For symptomatic control, doses of 0.5 mg to 2.5 mg are given by IM or SC injection at intervals throughout the day as needed. The total daily dose typically ranges from 5 mg to 20 mg.[24]
• Oral (historical): The oral dose range was wide, from 15 mg to 375 mg per day, divided into multiple doses.[24]
• Myasthenia Gravis (Pediatrics):
• Injectable: The dose is 0.01-0.04 mg/kg per dose (IV/IM/SC), administered every 2-3 hours as needed.[24] For neonates with transient myasthenia, the dose is 0.05-0.25 mg IM every 2-4 hours, typically given 30 minutes before feeding.[33]
• Postoperative Atony/Retention: For prophylaxis, a dose of 0.25 mg IM or SC is used. For treatment, the dose is 0.5 mg to 1 mg IM or SC, which can be repeated.[24]

C. Essential Monitoring and Administration Practices

The safe and effective use of Neostigmine, particularly for NMB reversal, is contingent upon strict adherence to established administration and monitoring protocols.

• Neuromuscular Monitoring: The use of a peripheral nerve stimulator to quantitatively assess the degree of neuromuscular blockade is considered the standard of care and is essential for guiding therapy. The train-of-four (TOF) count and ratio are the key parameters. Neostigmine should not be administered until there is clear evidence of spontaneous recovery from the block (e.g., a TOF count of at least 2, or a first twitch response that is >10% of the baseline value).[1] The ultimate goal of reversal is to achieve a TOF ratio of ≥0.9, which indicates adequate recovery of muscle function for safe tracheal extubation.[1]
• Anticholinergic Co-administration: Due to the profound muscarinic effects of Neostigmine, the co-administration of an anticholinergic agent is mandatory. Glycopyrrolate (at a dose of 0.2 mg for every 1 mg of Neostigmine) or atropine (at a dose of 0.02-0.03 mg/kg, or 0.6-1.2 mg for an adult) must be administered either just prior to or concomitantly with Neostigmine.[1] This practice is crucial for preventing or mitigating side effects, most notably severe bradycardia. In patients who are already bradycardic, the anticholinergic agent should always be administered first.[24]

Table 1: Dosing Guidelines for Neostigmine by Indication
Indication
Reversal of Non-Depolarizing Neuromuscular Blockade
Myasthenia Gravis (Symptomatic Treatment)
Myasthenia Gravis (Symptomatic Treatment)
Myasthenia Gravis (Diagnosis)
Postoperative Urinary Retention / Intestinal Atony
Acute Colonic Pseudo-obstruction (Ogilvie Syndrome)

VI. Safety Profile and Risk Mitigation

A. Adverse Drug Reactions

The adverse effect profile of Neostigmine is extensive but highly predictable, as the majority of side effects are direct pharmacological consequences of increased acetylcholine stimulating muscarinic and nicotinic receptors throughout the body.[1]

• Cardiovascular: Bradycardia is the most common and clinically significant cardiovascular effect. Other reactions include hypotension, various cardiac arrhythmias (such as atrioventricular (A-V) block and junctional escape rhythms), syncope, and, in rare cases, cardiac arrest. These effects are mediated by muscarinic receptor stimulation in the heart.[1]
• Respiratory: Bronchoconstriction and bronchospasm are potentially life-threatening adverse effects, particularly in patients with pre-existing asthma or reactive airway disease. Increased pharyngeal and bronchial secretions can also compromise the airway. In cases of overdose or improper administration, respiratory depression and arrest can occur.[1]
• Gastrointestinal: GI side effects are very common and include nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, and marked hypersalivation.[1]
• Neuromuscular: While the intended effect is to improve muscle strength, Neostigmine can cause paradoxical muscle weakness, particularly when administered in large doses or when the existing neuromuscular blockade is minimal. This is thought to be due to desensitization of ACh receptors from excessive stimulation. Muscle cramps, spasms, and fasciculations are also reported.[1]
• Ocular: Stimulation of muscarinic receptors in the eye leads to miosis (pupillary constriction), increased lacrimation (tearing), and can cause blurred vision.[4]
• Dermatologic and Allergic: Increased sweating (diaphoresis) is a common cholinergic effect. While rare, serious hypersensitivity reactions, including rash, urticaria, angioedema, and anaphylaxis, have been reported. Because of this risk, atropine and other medications for treating anaphylaxis should be readily available during administration.[1]

B. Contraindications, Warnings, and Precautions

The use of Neostigmine is strictly contraindicated in certain situations, and requires significant caution in others.

• Absolute Contraindications:
• Known hypersensitivity to Neostigmine or any of its components. Formulations containing bromide (i.e., neostigmine bromide) are contraindicated in patients with a history of bromide sensitivity.[25]
• Mechanical obstruction of the gastrointestinal or urinary tract. Stimulating motility or bladder contraction in the presence of a physical blockage can lead to perforation or rupture.[1]
• Peritonitis.[7]
• Warnings and Precautions:
• Cardiovascular Disease: Extreme caution is warranted in patients with coronary artery disease, recent myocardial infarction, or pre-existing cardiac arrhythmias. The risk of bradycardia and hypotension is significantly increased in this population, and continuous ECG and blood pressure monitoring during and after administration is strongly recommended.[1]
• Respiratory Disease: Neostigmine should be used with caution in patients with a history of asthma or bronchospastic disease due to the risk of inducing bronchoconstriction.[42]
• Other Coexisting Conditions: Caution is also advised in patients with epilepsy, hyperthyroidism, peptic ulcer disease, and vagotonia, as cholinergic stimulation can exacerbate these conditions.[40]
• Renal and Hepatic Impairment: Neostigmine's elimination is prolonged in patients with renal impairment. While specific dose adjustments are not mandated, these patients require close and extended monitoring for both the effects of Neostigmine and the potential for recurarization from renally cleared NMBAs.[1] Caution is also advised in patients with hepatic impairment, as the drug is partially metabolized by the liver.[1]
• Pregnancy: Neostigmine is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. It has the potential to cause uterine irritability and may induce premature labor if administered intravenously near term. Therefore, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.[1]

C. Clinically Significant Drug-Drug Interactions

Neostigmine's mechanism of action predisposes it to several important drug-drug interactions.

• Neuromuscular Blocking Agents:
• Non-depolarizing (e.g., rocuronium, vecuronium): Neostigmine antagonizes their neuromuscular blocking effects. This is the intended therapeutic interaction used for reversal.[25]
• Depolarizing (e.g., succinylcholine): Neostigmine inhibits the enzyme (pseudocholinesterase) that metabolizes succinylcholine. This potentiates the Phase I block of succinylcholine, leading to a prolonged and deepened paralysis. Co-administration is contraindicated.[1]
• Antibiotics: Certain antibiotics, particularly aminoglycosides (e.g., streptomycin, neomycin, gentamicin) and clindamycin, possess intrinsic neuromuscular blocking properties. When used concurrently with Neostigmine, they can antagonize its reversal effects and may necessitate dosage adjustments and careful monitoring.[1]
• Cardiovascular Drugs: Co-administration with beta-blockers can have an additive effect, worsening bradycardia.[25] There is also a risk of additive depressant effects on cardiac conduction when used with agents like calcium channel blockers and certain antiarrhythmics (e.g., procainamide, quinidine).[11]
• Other Cholinergic and Anticholinergic Drugs: Neostigmine will have additive effects when used with other cholinesterase inhibitors or cholinomimetic drugs. Conversely, its effects are directly antagonized by anticholinergic (antimuscarinic) drugs like atropine, glycopyrrolate, and diphenhydramine.[11]

D. Overdose and Management of Cholinergic Crisis

Overdosage with Neostigmine leads to a state of excessive cholinergic stimulation known as a cholinergic crisis, which is a medical emergency.

• Definition and Symptoms: A cholinergic crisis is characterized by an overabundance of acetylcholine at both muscarinic and nicotinic receptors.[7] Muscarinic symptoms include nausea, vomiting, diarrhea, profuse sweating, excessive salivation and bronchial secretions, miosis, and severe bradycardia. Nicotinic symptoms manifest as muscle fasciculations, cramps, and, critically, profound muscle weakness that progresses to flaccid paralysis. Death can result from respiratory muscle paralysis or cardiac arrest.[29]
• Differentiation from Myasthenic Crisis: Differentiating a cholinergic crisis from a myasthenic crisis (caused by undertreatment or exacerbation of myasthenia gravis) is a critical diagnostic challenge, as both conditions present with extreme muscle weakness. Clinical context is key. A "Tensilon test," using a short-acting cholinesterase inhibitor like edrophonium, can be diagnostic: a temporary improvement in strength suggests a myasthenic crisis, whereas a worsening of weakness indicates a cholinergic crisis. This test must be performed with caution and with resuscitation equipment immediately available.[7]
• Management: The management of a cholinergic crisis requires immediate and aggressive intervention. All cholinesterase inhibitor medications must be discontinued immediately. The primary antidote for the life-threatening muscarinic effects is atropine, administered intravenously in doses of 1-2 mg and repeated as necessary. The most critical intervention is supportive care, particularly securing the airway and providing mechanical ventilation to manage respiratory paralysis.[29]

Table 2: Summary of Adverse Reactions by System Organ Class
System Organ Class
Cardiovascular
Respiratory
Gastrointestinal
Neuromuscular
Ocular
Allergic / Skin

VII. Comparative Therapeutic Analysis

A. Neostigmine vs. Other Clinically Relevant AChE Inhibitors

Neostigmine belongs to a class of carbamate AChE inhibitors that includes physostigmine and pyridostigmine. Understanding their structural and pharmacokinetic differences is key to appreciating their distinct clinical roles.

• Neostigmine vs. Physostigmine:
• Structural and Pharmacokinetic Differences: The defining difference lies in their chemical structure. Neostigmine is a quaternary amine, possessing a permanent positive charge, while physostigmine is a tertiary amine, which is uncharged at physiological pH.[11] This single chemical distinction has profound pharmacokinetic consequences. As a charged molecule, Neostigmine cannot cross the blood-brain barrier (BBB), confining its actions to the periphery. In contrast, the lipid-soluble physostigmine readily penetrates the BBB and exerts significant effects within the central nervous system.[11] Furthermore, Neostigmine has a slightly slower onset of action (7-11 minutes) and a longer duration (60-120 minutes) compared to the more rapid onset (3-8 minutes) and shorter duration (30-90 minutes) of physostigmine.[11]
• Clinical Application Differences: These pharmacokinetic profiles dictate their primary, non-overlapping clinical uses. Neostigmine is the agent of choice for peripheral applications where CNS effects are undesirable, such as the reversal of neuromuscular blockade and the symptomatic treatment of myasthenia gravis. Physostigmine, conversely, is the specific antidote for central anticholinergic syndrome (e.g., from atropine or tricyclic antidepressant overdose), where its ability to counteract cholinergic deficits within the brain is essential.[11]
• Neostigmine vs. Pyridostigmine (in Myasthenia Gravis):
• Key Differences: Both are quaternary amine AChE inhibitors used in myasthenia gravis, but they differ in their kinetic profiles. Pyridostigmine has a slower onset of action but a significantly longer duration of action compared to Neostigmine. Pyridostigmine is also less potent on a milligram-for-milligram basis.[22]
• Clinical Preference: For the chronic, long-term oral management of myasthenia gravis, pyridostigmine (Mestinon) is overwhelmingly preferred. Its longer duration of action allows for less frequent dosing (typically 3-4 times a day) and provides a smoother, more sustained level of muscle strength throughout the day. Its lower potency can also make dose titration easier and may be associated with better gastrointestinal tolerability.[27] Neostigmine's role in myasthenia gravis is now largely confined to parenteral administration for acute management (e.g., in hospitalized patients who cannot take oral medications) or for diagnostic testing.[52]
• Dosing Equivalence: When switching between these agents, established dose equivalencies are used. Approximately 15 mg of oral neostigmine bromide is equivalent to 0.5 mg of parenteral neostigmine methylsulfate. For myasthenia gravis, 60 mg of oral pyridostigmine is considered equivalent to 1-1.5 mg of parenteral neostigmine.[43]

B. Neostigmine vs. Sugammadex: The Old Guard and the New

The introduction of Sugammadex has created a paradigm shift in the reversal of neuromuscular blockade, establishing a direct competitor to Neostigmine.

• Mechanism of Action: The two drugs operate via fundamentally different mechanisms. Neostigmine is an indirect-acting agent that increases the concentration of ACh to compete with the NMB agent at the receptor. Sugammadex is a selective relaxant-binding agent (SRBA); it is a modified gamma-cyclodextrin designed to directly encapsulate and inactivate steroidal NMBAs (specifically rocuronium and vecuronium) in the plasma, forming a stable, inactive complex that is then excreted.[35]
• Efficacy: Clinical evidence overwhelmingly shows that Sugammadex provides a much faster, more reliable, and more complete reversal of neuromuscular blockade compared to Neostigmine. This superiority is most pronounced in the reversal of deep and profound levels of blockade, a clinical scenario where Neostigmine is ineffective and its use is contraindicated.[35]
• Safety Profile: Because Sugammadex does not interact with the cholinergic system, it is devoid of the muscarinic side effects associated with Neostigmine. This eliminates the need for co-administration of an anticholinergic agent and results in a significantly lower incidence of postoperative adverse events such as nausea, vomiting, and cardiovascular disturbances.[1]
• Clinical Implications: The development of Sugammadex represents a major advance, offering a more targeted, effective, and safer alternative for the reversal of steroidal NMBAs. However, Neostigmine retains a crucial place in clinical practice. It is effective for reversing non-steroidal NMBAs (such as cisatracurium and atracurium), for which Sugammadex is not indicated. Furthermore, as a long-established generic medication, Neostigmine is significantly more cost-effective, ensuring its continued use as a first-line or primary reversal agent in many healthcare systems and clinical situations worldwide.[13]

Table 3: Comparative Profile of Clinically Used AChE Inhibitors
Drug
Neostigmine
Physostigmine
Pyridostigmine
Data compiled from 11

Table 4: Neostigmine vs. Sugammadex for NMB Reversal
Feature
Mechanism of Action
Target NMBAs
Efficacy in Deep Block
Speed of Reversal
Need for Anticholinergic
Key Adverse Effects
Cost
Data compiled from 1

VIII. Global Regulatory Status and Market Context

A. United States (FDA)

Neostigmine has a unique and lengthy regulatory history with the U.S. Food and Drug Administration (FDA).

• Approval History: It was first approved in 1939 under the brand name Prostigmin (NDA 654), long before modern regulatory standards were established.[6] More recent formulations, such as Bloxiverz (NDA 204078), gained approval through the 505(b)(2) regulatory pathway. This pathway allows manufacturers to rely on published literature and the FDA's previous findings of safety and effectiveness for the active ingredient, given its long history of clinical use, rather than conducting entirely new clinical trials.[54]
• Approved Indications: The primary and formally approved indication for modern Neostigmine formulations in the U.S. is the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.[1]
• Orphan Drug Status: In 2012, Neostigmine methylsulfate was granted an orphan drug designation for the treatment of Myasthenia Gravis by the FDA. This designation provides incentives for the development of drugs for rare diseases. However, this was not pursued to a full marketing approval for this specific indication.[24]
• Post-marketing Requirements: Despite its long history, Neostigmine is not exempt from modern regulatory scrutiny. The FDA has imposed post-marketing requirements on newer approvals, such as conducting studies on extractables and leachables from the vial stoppers and container closure systems, to ensure they meet contemporary safety standards.[5]

B. Europe (EMA and National Agencies)

The regulatory status of Neostigmine in Europe differs from that in the U.S.

• Regulatory Status: Neostigmine does not appear to hold a centralized marketing authorization from the European Medicines Agency (EMA). Instead, it is authorized at the national level in numerous individual European member states, such as the United Kingdom and Germany, where it has been available for many years.[48] Consequently, there is no single, comprehensive European Public Assessment Report (EPAR) for Neostigmine itself.[58]
• Role as a Comparator: Neostigmine's status as the established standard of care for NMB reversal is solidified by its frequent use as the active comparator in the EMA's clinical assessment of new reversal agents. For instance, in the EPAR for Sugammadex (Bridion), Neostigmine was the benchmark against which Sugammadex's efficacy and safety were measured and ultimately proven superior.[35]
• European Pharmacopoeia (EP): Neostigmine bromide is listed as an official EP Reference Standard, which underscores its recognized status and importance in pharmaceutical quality control standards across Europe.[59]

C. Market Landscape

The market for Neostigmine is mature but dynamic, influenced by surgical volumes, generic competition, and the emergence of new technologies.

• Market Size and Growth: The global market for Neostigmine methylsulfate injection was estimated to be valued at USD 171.5 million in 2025 and is projected to grow, driven primarily by the high and increasing number of surgical procedures performed worldwide.[13]
• Regional Dominance: North America currently represents the largest market for Neostigmine, followed by Europe. This is attributed to the high volume of surgeries and the established use of reversal agents in these regions.[13]
• Competitive Environment: The market is characterized by a mix of branded products (e.g., Bloxiverz) and numerous low-cost generic versions. The most significant competitive pressure comes from the alternative reversal agent, Sugammadex, which, despite its higher cost, offers superior efficacy and safety for reversing steroidal NMBAs.[13] In response to this competition, value-added formulations have been introduced, such as the fixed-dose combination product PREVDUO (Neostigmine/Glycopyrrolate), which aims to improve convenience and safety, thereby defending a market niche for this older molecule.[13]

The regulatory and market history of Neostigmine provides a compelling illustration of the lifecycle of a legacy drug in the modern pharmaceutical era. Approved in 1939 under vastly different standards, new formulations today cannot simply be "grandfathered in." Manufacturers must navigate complex modern regulatory pathways like the 505(b)(2), leveraging decades of public data while still meeting stringent contemporary standards for chemistry, manufacturing, and controls (CMC), including detailed studies on potential contaminants from packaging.[54] This presents a regulatory paradox: the drug is universally accepted as a standard of care, yet new versions face a high bar for approval. On the market side, Neostigmine faces a classic pincer movement: intense price pressure from numerous generic competitors on one side, and clinical pressure from a more effective but significantly more expensive innovative competitor (Sugammadex) on the other.[13] The development of value-added products like the PREVDUO combination syringe is a direct strategic response to this pressure, representing an attempt to innovate around an old molecule to maintain its relevance and market share.[13] This entire narrative serves as a case study in the challenges and strategies surrounding legacy pharmaceuticals in the 21st century.

IX. Synthesis and Concluding Remarks

This report has provided a comprehensive, multi-faceted analysis of Neostigmine, a venerable and indispensable parasympathomimetic agent. Synthesizing decades of clinical use with modern pharmacological and regulatory data reveals a drug whose profile is thoroughly understood. Neostigmine's mechanism as a non-selective, reversible acetylcholinesterase inhibitor is the source of both its therapeutic efficacy and its predictable, manageable adverse effects. Its pharmacology is a classic example of a "double-edged sword," where the desired nicotinic stimulation at the neuromuscular junction is inseparable from the undesired muscarinic effects that necessitate vigilant monitoring and mandatory co-administration of anticholinergic agents.

Despite its age and the emergence of more sophisticated, targeted therapies, Neostigmine retains significant and enduring clinical value. Its ability to reverse the effects of all non-depolarizing neuromuscular blocking agents—both steroidal and non-steroidal—gives it a broader spectrum of activity than its main competitor, Sugammadex. This, combined with extensive clinical experience and its low cost as a generic medication, ensures its continued role as a first-line or essential agent in many clinical scenarios and healthcare systems around the world. It remains a vital tool in the clinician's armamentarium, a testament to a robust and reliable, albeit imperfect, mechanism.

However, the limitations of Neostigmine must be acknowledged. Its narrow therapeutic window, the ceiling effect on its efficacy, its inability to reliably reverse deep or profound neuromuscular blockade, and the absolute requirement for anticholinergic co-administration represent significant drawbacks. The comparison with Sugammadex highlights a clear and ongoing trend in pharmacology toward the development of more targeted, mechanism-based therapies that offer superior safety and efficacy profiles. This trend represents the future of neuromuscular pharmacology. While Neostigmine is no longer the only option for neuromuscular blockade reversal, and is no longer the preferred agent for chronic myasthenia gravis management, it remains a fundamental and essential medication, bridging the history of pharmacology with the demands of modern clinical practice.

Works cited

1. Neostigmine - StatPearls - NCBI Bookshelf, accessed August 1, 2025, https://www.ncbi.nlm.nih.gov/books/NBK470596/
2. Neostigmine | C12H19N2O2+ | CID 4456 - PubChem, accessed August 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/59-99-4
3. Neostigmine - eDrug, accessed August 1, 2025, https://edrug.mvm.ed.ac.uk/index.php/drug/neostigmine/
4. Neostigmine - Wikipedia, accessed August 1, 2025, https://en.wikipedia.org/wiki/Neostigmine
5. 203629Orig1s000 - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203629Orig1s000SumR.pdf
6. 203629Orig1s000 - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203629Orig1s000CrossR.pdf
7. neostigmine methylsulfate injection - This label may not be the latest ..., accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203629s003lbl.pdf
8. New advances in clinical application of neostigmine: no longer focusing solely on increasing skeletal muscle strength - Frontiers, accessed August 1, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1227496/full
9. www.mayoclinic.org, accessed August 1, 2025, https://www.mayoclinic.org/drugs-supplements/neostigmine-injection-route/description/drg-20071686#:~:text=Neostigmine%20injection%20is%20used%20to,used%20to%20relax%20the%20muscles.
10. Neostigmine | CAS#59-99-4 | cholinesterase inhibitor - MedKoo Biosciences, accessed August 1, 2025, https://www.medkoo.com/products/20321
11. PHYSOSTIGMINE AND NEOSTIGMINE | Poisoning & Drug ..., accessed August 1, 2025, https://accessmedicine.mhmedical.com/content.aspx?sectionid=248385963
12. Neuromuscular Blockade Completed Phase Trials for Neostigmine (DB01400) - DrugBank, accessed August 1, 2025, https://go.drugbank.com/indications/DBCOND0033485/clinical_trials/DB01400?status=completed
13. Neostigmine Methylsulfate Injection MarketSize and Trends - Coherent Market Insights, accessed August 1, 2025, https://www.coherentmarketinsights.com/market-insight/neostigmine-methylsulfate-injection-market-6033
14. Neostigmine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 1, 2025, https://go.drugbank.com/drugs/DB01400
15. CAS No : 59-99-4 | Product Name : Neostigmine - API - Pharmaffiliates, accessed August 1, 2025, https://www.pharmaffiliates.com/en/59-99-4-neostigmine-api-pa141280000.html
16. 59-99-4 Neostigmine AKSci 0502CA - AK Scientific, accessed August 1, 2025, https://aksci.com/item_detail.php?cat=0502CA
17. Neostigmine - the NIST WebBook - National Institute of Standards and Technology, accessed August 1, 2025, https://webbook.nist.gov/cgi/cbook.cgi?ID=59-99-4
18. Neostigmine - brand name list from Drugs.com, accessed August 1, 2025, https://www.drugs.com/ingredient/neostigmine.html
19. Neostigmine (Bloxiverz): Drug Basics and Frequently Asked Questions - GoodRx, accessed August 1, 2025, https://www.goodrx.com/neostigmine-methylsulfate/what-is
20. Neostigmine | Drug Lookup | Pediatric Care Online - AAP Publications, accessed August 1, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5743/Neostigmine-Systemic
21. Neostigmine methylsulfate | CAS#51-60-5 | 59-99-4 - MedKoo Biosciences, accessed August 1, 2025, https://www.medkoo.com/products/8996
22. Neostigmine bromide | myaware, accessed August 1, 2025, https://www.myaware.org/neostigmine-bromide
23. Prevduo (neostigmine/glycopyrrolate) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 1, 2025, https://reference.medscape.com/drug/prevduo-neostigmine-glycopyrrolate-4000373
24. Bloxiverz (neostigmine) dosing, indications, interactions, adverse ..., accessed August 1, 2025, https://reference.medscape.com/drug/bloxiverz-neostigine-343064
25. Neostigmine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 1, 2025, https://www.pediatriconcall.com/drugs/neostigmine/801
26. New advances in clinical application of neostigmine: no longer focusing solely on increasing skeletal muscle strength - PubMed Central, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10436336/
27. Indirect Acting: Physostigmine, Neostigmine, Pyridostigmine, Edrophonium chloride, accessed August 1, 2025, https://www.pharmaguideline.com/2022/03/indirect-acting-physostigmine-neostigmine-pyridostgmine-edrphonium-chloride.html
28. Pharmacokinetics and pharmacological effects of neostigmine in man - PMC, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1429427/
29. Neostigmine Monograph for Professionals - Drugs.com, accessed August 1, 2025, https://www.drugs.com/monograph/neostigmine.html
30. What is the use of neostigmine (an acetylcholinesterase inhibitor)? - Dr.Oracle AI, accessed August 1, 2025, https://www.droracle.ai/articles/76173/use-of-neostigmine
31. Neostigmine tablets - Cleveland Clinic, accessed August 1, 2025, https://my.clevelandclinic.org/health/drugs/20042-neostigmine-tablets
32. Effective Myasthenia Gravis Medications: Prostigmin, Mestinon, and Key Therapies, accessed August 1, 2025, https://www.mamahealth.com/myasthenia-gravis/medications
33. Neostigmine Methylsulfate Injection, solution for injection, 2.5 mg/mL - Medsafe, accessed August 1, 2025, https://www.medsafe.govt.nz/profs/datasheet/n/neostigmineMaxinj.pdf
34. Neostigmine Recruiting Phase Trials for Neuromuscular Inhibition Treatment - DrugBank, accessed August 1, 2025, https://go.drugbank.com/drugs/DB01400/clinical_trials?conditions=DBCOND0051706&phase=&purpose=treatment&status=recruiting
35. Bridion | European Medicines Agency (EMA), accessed August 1, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/bridion
36. Neostigmine Unknown Status Phase 1 Trials for Spinal Cord Injuries / Neurogenic Bowel Dysfunction Treatment - DrugBank, accessed August 1, 2025, https://go.drugbank.com/drugs/DB01400/clinical_trials?conditions=DBCOND0076226%2CDBCOND0028058&phase=1&purpose=treatment&status=unknown_status
37. Acetylcholinesterase inhibitor treatment for myasthenia gravis | Request PDF, accessed August 1, 2025, https://www.researchgate.net/publication/49842841_Acetylcholinesterase_inhibitor_treatment_for_myasthenia_gravis
38. Acetylcholinesterase inhibitor treatment for myasthenia gravis - Cochrane, accessed August 1, 2025, https://www.cochrane.org/evidence/CD006986_acetylcholinesterase-inhibitor-treatment-myasthenia-gravis
39. Neostigmine Methylsulfate Injection, USP - American Regent, accessed August 1, 2025, https://www.americanregent.com/media/1773/neostigmine-prescribing-information.pdf
40. NEW ZEALAND DATA SHEET 1. PRODUCT NAME NEOSTIGMINE METHYLSULFATE INJECTION B.P. Solution for injection 2.5 mg/mL. 2. QUALITATIV - Medsafe, accessed August 1, 2025, https://www.medsafe.govt.nz/profs/datasheet/n/Neostigmineinj.pdf
41. Neostigmine injection - Cleveland Clinic, accessed August 1, 2025, https://my.clevelandclinic.org/health/drugs/18123-neostigmine-injection
42. Neostigmine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 1, 2025, https://www.rxlist.com/neostigmine/generic-drug.htm
43. Neostigmine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 1, 2025, https://www.drugs.com/dosage/neostigmine.html
44. Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection): Side Effects, Uses, Dosage, Interactions, Warnings - Rx List, accessed August 1, 2025, https://www.rxlist.com/neostigmine-drug.htm
45. Neostigmine (oral route) - Side effects & dosage - Mayo Clinic, accessed August 1, 2025, https://www.mayoclinic.org/drugs-supplements/neostigmine-oral-route/description/drg-20071653
46. Neostigmine (injection route) - Side effects & uses - Mayo Clinic, accessed August 1, 2025, https://www.mayoclinic.org/drugs-supplements/neostigmine-injection-route/description/drg-20071686
47. Showing BioInteractions for Neostigmine (DB01400) | DrugBank Online, accessed August 1, 2025, https://go.drugbank.com/drugs/DB01400/biointeractions
48. Neostigmine Methylsulfate Injection BP 2.5mg in 1ml - Summary of ..., accessed August 1, 2025, https://www.medicines.org.uk/emc/product/6268/smpc
49. Myasthenia gravis (Chapter 110) - Essential Clinical Anesthesia Review, accessed August 1, 2025, https://www.cambridge.org/core/books/essential-clinical-anesthesia-review/myasthenia-gravis/BA6A034AF96C65ABE75257C267E9080B
50. Neostigmine Bromide Tablets15mg - Summary of Product Characteristics (SmPC) - (emc), accessed August 1, 2025, https://www.medicines.org.uk/emc/product/2849/smpc
51. Neostigmine versus pyridostigmine - NUS Blog, accessed August 1, 2025, https://blog.nus.edu.sg/phcdgs/2020/02/22/neostigmine-versus-pyridostigmine/
52. Switching between neostigmine and pyridostigmine – SPS - Specialist Pharmacy Service, accessed August 1, 2025, https://www.sps.nhs.uk/articles/switching-between-neostigmine-and-pyridostigmine/
53. Sugammadex in the management of myasthenic patients undergoing surgery: beyond expectations - Carron - Annals of Translational Medicine, accessed August 1, 2025, https://atm.amegroups.org/article/view/31198/html
54. 204078Orig1s000 - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204078Orig1s000SumR.pdf
55. Search Orphan Drug Designations and Approvals - FDA, accessed August 1, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=359611
56. Neostigmine Methylsulfate Injection, 0.5mg/mL and 1 mg/mL - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/203629Orig1s000ltr.pdf
57. EU Clinical Trials Register, accessed August 1, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000692-92/AT
58. European public assessment report | European Medicines Agency (EMA), accessed August 1, 2025, https://www.ema.europa.eu/en/glossary-terms/european-public-assessment-report
59. Neostigmine bromide EP Reference Standard CAS 114-80-7 Sigma Aldrich, accessed August 1, 2025, https://www.sigmaaldrich.com/US/en/product/sial/n0500000